🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study to Evaluate the Impact of the Recovery Pathway on Postoperative Leght of Stay in Coronary Artery Bypass Surgery

RecruitingNAAges any - anyAllUniversity of Sao Paulo General Hospital
NCT06713096 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This randomized and prospective trial aims to evaluate the implementation of a rapid recovery protocol for coronary artery bypass grafting (CABG) in a hospital serving patients from the Brazilian Unified Health System (Sistema Único de Saúde - SUS). The study will compare outcomes between two groups: patients receiving care under the rapid recovery protocol and those following the standard institutional care. Primary Objective: Compare postoperative hospital stay between the rapid recovery group and the usual care group. Secondary Objectives: Assess morbidity and mortality between both groups. Evaluate patient satisfaction using validated tools. Analyze incremental costs associated with both approaches. Assess healthcare teams' learning progression regarding the protocol (Kirkpatrick method). Evaluate adherence to rapid recovery protocol metrics by healthcare teams. Measure chan

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (\>18 years old) * Undergoing isolated coronary artery bypass grafting (CABG) with elective or urgent status * Signed informed consent form (ICF) Exclusion Criteria: * Emergency patients * Severe ventricular dysfunction (ejection fraction \<30%) * Renal impairment (creatinine clearance \<30 mL/min) * Atrial fibrillation or need for oral anticoagulation * Moderate-to-severe anemia (hematocrit \<32%) * STS risk score \>4% * Patient and/or family disagreement with the protocol * Failure to sign the informed consent form
💊

What it tests

  • Tempos Certos protocol
📍

Where

1 site
Hc Da Fmusp Instituto Do Coracao Incor Sao Paulo
São Paulo, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy